Posted by Michael Wonder on 16 Mar 2022
PHARMAC to fund new treatments for lung and ovarian cancer
16 March 2022 - PHARMAC has confirmed today they are funding a bundle deal which will give New Zealanders more effective treatment options for lung cancer and ovarian cancer.
The bundle deal also includes a new medicine for people with severe eosinophilic asthma.
The bundle deal with pharmaceutical company AstraZeneca is for:
- Durvalumab (Imfinzi) for people with stage 3 non-small-cell lung cancer
- Widened access to olaparib (Lynparza) to include first line treatment of people with certain types of high-grade ovarian cancer
- Benralizumab (Fasenra) providing an additional treatment option for people with severe eosinophilic asthma
- Discounts on three already funded medicines - budesonide with eformoterol powder for inhalation (Symbicort Turbuhaler), fulvestrant (Faslodex) and gefitinib (Iressa)
